Can Lunesta (eszopiclone) increase the risk of dementia, particularly in older adults with pre-existing cognitive impairments?

Can Lunesta Cause Dementia?

While Lunesta (eszopiclone) has not been definitively proven to cause dementia, it is associated with significant cognitive impairment risks, particularly in older adults, and guidelines specifically warn that hypnotics used regularly and long-term are associated with dementia. 1

Evidence Linking Hypnotics to Dementia Risk

The American College of Physicians explicitly notes that hypnotics used regularly and long-term are associated with dementia, fractures, major injuries, and possibly cancer. 1 This represents a class-wide concern that extends to eszopiclone as a nonbenzodiazepine hypnotic agent.

Research on benzodiazepines, a related class of medications, demonstrates an emerging concern about a potentially increased risk of dementia with chronic use. 2 While eszopiclone is a nonbenzodiazepine, it acts on the same GABAA receptor complex and shares similar mechanisms of action.

Direct Cognitive Effects of Eszopiclone

Eszopiclone causes documented CNS depression with adverse effects including dizziness, confusion, and cognitive impairment. 1 The FDA label confirms that:

• Memory impairment and confusion occur in clinical trials, with rates of 1-3% in patients treated with eszopiclone compared to 0% with placebo 3
• Next-morning psychomotor and memory impairment persists up to 11.5 hours after dosing, even when patients subjectively feel normal 3
• Amnesia and other neuropsychiatric symptoms may occur unpredictably 3

Comparative Evidence: Z-Drugs vs. Benzodiazepines

A 2021 study specifically examining Z-drugs (including eszopiclone) in middle-aged and older patients with chronic insomnia found that benzodiazepine exposure density was an independent risk factor for cognitive impairment, but no correlation was found between Z drug use and cognitive impairment. 4 In fact, Z drug use appeared to be associated with protection for attention. 4

This suggests that while eszopiclone may be safer than benzodiazepines regarding long-term dementia risk, the absence of evidence is not evidence of absence—high-quality long-term data in older adults remain lacking.

Critical Gaps in Evidence

The American Academy of Sleep Medicine states that high-quality data to support the use of newer nonbenzodiazepine hypnotics like eszopiclone in demented older adults are nonexistent. 1 The longest clinical trials of eszopiclone were only 6-12 months in duration, with the oldest participant being 69 years old. 5 This means we lack data on:

• Long-term use (>1 year) in the "old old" (75-84 years) and "oldest old" (85+ years) 5
• Whether chronic use accelerates cognitive decline or increases dementia risk over years of exposure
• The cumulative effect of nightly cognitive impairment on brain health

High-Risk Populations

Older adults face particularly severe risks including cognitive impairment, falls, and unsafe mobility. 1 The American Academy of Sleep Medicine suggests avoiding or using extreme caution in elderly patients with existing cognitive impairment. 1

The American College of Physicians advises dose reduction in older/debilitated adults because drugs remain at levels high enough to interfere with morning function. 1 Maximum dose should not exceed 2 mg in elderly patients. 3

Clinical Recommendations

Given the evidence:

• Avoid eszopiclone in patients with pre-existing cognitive impairment or dementia 1
• Use the lowest effective dose (1 mg for elderly patients) to minimize cognitive and behavioral risks 1
• Limit duration of use—the American Academy of Sleep Medicine recommends tapering within 3-6 months for agitated dementia to determine the lowest effective maintenance dose 6
• Monitor closely for memory impairment, confusion, and next-day cognitive dysfunction 3
• Consider cognitive-behavioral therapy for insomnia as first-line treatment in older adults, as it effectively targets behavioral factors maintaining chronic insomnia without medication risks 5

Common Pitfalls to Avoid

• Do not assume eszopiclone is safe simply because it is commonly prescribed—guidelines explicitly warn about long-term hypnotic use and dementia risk 1
• Do not rely on patient self-report of cognitive function—impairment can occur in the absence of symptoms or with subjective improvement, and may not be reliably detected by ordinary clinical exam 3
• Do not prescribe long-term without attempting periodic discontinuation—chronic use may lead to tolerance and dependence without clear evidence of sustained benefit in the very old 5